Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 7, 2006; 12(33): 5293-5300
Published online Sep 7, 2006. doi: 10.3748/wjg.v12.i33.5293
Published online Sep 7, 2006. doi: 10.3748/wjg.v12.i33.5293
Table 1 Baseline characteristics of patients (Information are not available for all patients) n (%)
| Characteristic | All(n = 188) | PegIFN +RBV + AMA(n = 106) | IFN+RBV+AMA(n = 82) |
| Male/Female | 146/42 | 79/27 | 67/15 |
| Age | |||
| ≤ 40 yr | 42 (22) | 23 (22) | 19 (23) |
| > 40 yr | 146 (78) | 83 (78) | 63 (77) |
| BMI | |||
| ≤ 25 kg/m2 | 107 (64) | 60 (65) | 47 (63) |
| > 25 kg/m2 | 61 (36) | 33 (35) | 28 (37) |
| ALT | |||
| ≤ 120 UI/L | 107 (62) | 64 (65) | 43 (58) |
| > 120 UI/L | 66 (38) | 35 (35) | 31 (42) |
| HCV genotype | |||
| 1 | 147 (78) | 82 (77) | 65 (79) |
| 2 | 21 (11) | 12 (11) | 9 (11) |
| 3 | 8 (4) | 7 (7) | 1 (1) |
| 4 | 12 (6) | 5 (5) | 7 (9) |
| HCV RNA | |||
| ≤ 2 x 106 copies/mL | 74 (73) | 41 (76) | 33 (69) |
| > 2 x 106 copies/mL | 28 (27) | 13 (24) | 15 (31) |
| Stage | |||
| ≤ 3 | 127 (69) | 71 (70) | 56 (68) |
| > 3 | 56 (31) | 30 (30) | 26 (32) |
| Grade | |||
| ≤ 10 | 167 (92) | 94 (91) | 73 (92) |
| > 10 | 15 (8) | 9 (9) | 6 (8) |
- Citation: Fargion S, Borzio M, Maraschi A, Cargnel A, Lombardo TPOTGE. Triple antiviral therapy in HCV positive patients who failed prior combination therapy. World J Gastroenterol 2006; 12(33): 5293-5300
- URL: https://www.wjgnet.com/1007-9327/full/v12/i33/5293.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i33.5293